Created at	Source	Raw Value	Validated value
Nov. 26, 2021, 10:30 p.m.	oms	1. Patients not providing consent for participation in the study <br/ >2. FEV1/FVC ratio < 0.80 <br/ >3. Active smokers <br/ >4. Any active malignancy/ malignancy within past 2 years <br/ >5. Severe hepatic impairment <br/ >6. Use of immunosuppressant drugs (except corticosteroids and tocilizumab) within last 6 weeks <br/ >	1. Patients not providing consent for participation in the study <br/ >2. FEV1/FVC ratio < 0.80 <br/ >3. Active smokers <br/ >4. Any active malignancy/ malignancy within past 2 years <br/ >5. Severe hepatic impairment <br/ >6. Use of immunosuppressant drugs (except corticosteroids and tocilizumab) within last 6 weeks <br/ >
Nov. 13, 2021, 5:33 p.m.	oms	N/A	N/A
May 27, 2021, 12:45 a.m.	oms	1. Patients not providing consent for participation in the study <br/ >2. FEV1/FVC ratio < 0.80 <br/ >3. Active smokers <br/ >4. Any active malignancy/ malignancy within past 2 years <br/ >5. Severe hepatic impairment <br/ >6. Use of immunosuppressant drugs (except corticosteroids and tocilizumab) within last 6 weeks <br/ >	1. Patients not providing consent for participation in the study <br/ >2. FEV1/FVC ratio < 0.80 <br/ >3. Active smokers <br/ >4. Any active malignancy/ malignancy within past 2 years <br/ >5. Severe hepatic impairment <br/ >6. Use of immunosuppressant drugs (except corticosteroids and tocilizumab) within last 6 weeks <br/ >